The urinary tract infection treatment market size has grown steadily in recent years. It will grow from $10.52 billion in 2024 to $10.78 billion in 2025 at a compound annual growth rate (CAGR) of 2.5%. The growth in the historic period can be attributed to antibiotic discoveries, urinary catheter use, clinical guidelines and protocols, patient awareness and education, women's health research.
The urinary tract infection treatment market size is expected to see steady growth in the next few years. It will grow to $12.45 billion in 2029 at a compound annual growth rate (CAGR) of 3.7%. The growth in the forecast period can be attributed to development of non-antibiotic treatments, rise in resistant bacterial strains, personalized treatment approaches, elemedicine and remote consultations, public health awareness programs. Major trends in the forecast period include microbiome-based therapies, phage therapy, point-of-care testing, nutritional interventions, preventive strategies focus, community-based interventions.
The increasing prevalence of urinary tract infections is poised to drive the expansion of the market for urinary tract infection treatment in the future. Urinary tract infections encompass bacterial infections affecting various parts of the urinary system, including the kidneys, bladder, ureters, and urethra. Effective treatment of urinary tract infections is crucial in addressing the infection and fostering healing. As of January 2023, the National Institute of Health reported that urinary tract infections ranked as the seventh most common reason for emergency department visits in the USA, constituting over one million annual visits. Of these cases, 22% (220,000) were considered complicated UTIs, with around 100,000 resulting in hospital admissions. Consequently, the increasing prevalence of urinary tract infections is a significant driver of growth in the urinary tract infection treatment market.
The aging population is anticipated to be a catalyst for the expansion of the urinary tract infection treatment market. The term 'aging population' refers to a demographic shift characterized by a rising proportion of elderly individuals within a society or population. The elderly demographic requires urinary tract infection (UTI) treatment due to an elevated susceptibility to UTIs associated with age-related factors such as weakened immune function and alterations in urinary tract structure. As of October 2022, the World Health Organization highlighted that the global population of individuals aged 60 years and older is rapidly growing, projected to double by 2050, reaching 2.1 billion. Hence, the increasing aging population is propelling the growth of the urinary tract infection treatment market.
The adoption of advanced diagnostic technologies is an emerging trend gaining traction in the urinary tract infection treatment market. Companies in the market are focusing on innovative product development to maintain their competitive positions. In April 2023, AccessDx Laboratory, a US-based diagnostic laboratory, introduced the UTI PROx Panel. UTI PROx is designed to provide healthcare providers with enhanced insights to improve clinical care and decision-making when dealing with suspected, complex, and recurrent urinary tract infections.
Major companies operating in the urinary tract infection treatment market are concentrating on the development of innovative products such as Harncare bearberry tablets. These tablets serve as an herbal remedy for symptoms associated with lower urinary tract infections. Harncare Bearberry Tablets, formulated with the single crude drug bearberry, is the first tablet of its kind in Japan and is available as a second-class over-the-counter drug in pharmacies and drugstores across the country. In March 2022, Taiho Pharmaceutical Co. Ltd., a Japan-based pharmaceutical company, launched Harncare Bearberry tablets, addressing urinating discomfort and the sensation of residual urine.
In September 2022, GSK plc, a UK-based biopharmaceutical company, announced a licensing agreement with Spero Therapeutics, Inc. for tebipenem pivoxil hydrobromide (tebipenem HBr). This partnership aims to enable GSK to develop and commercialize tebipenem HBr, an innovative oral antibiotic designed to treat complicated urinary tract infections, thereby addressing a critical unmet medical need for effective alternatives to intravenous therapies. Spero Therapeutics, Inc. is a US-based biopharmaceutical company focused on treating urinary tract infections.
Major companies operating in the urinary tract infection treatment market include Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck & Co. Inc, AbbVie Inc., Allergan Plc, Bayer AG, Novartis International AG., Sanofi S.A., Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., AstraZeneca plc, GlaxoSmithKline PLC, Eli Lilly and Company, Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries Ltd, Dr. Reddy's Laboratories Ltd., Bio-Rad Laboratories Inc., Cipla Ltd, Hikma Pharmaceuticals PLC, Lupin Limited, Almirall SA, Torrent Pharmaceuticals Limited, Glenmark Pharmaceuticals Limited, Mylan N.V.
North America was the largest region in the urinary tract infection treatment market in 2024. The regions covered in the urinary tract infection treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the urinary tract infection treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Urinary tract infection treatment involves medical procedures and methods aimed at eliminating bacterial infections affecting the urinary system, which can impact areas such as the bladder, urethra, ureters, kidneys, and other components of the urinary system.
The main types of drug classes in urinary tract infection treatment include penicillin and combinations, quinolones, cephalosporin, aminoglycoside antibiotics, Sulfonamides, azoles and amphotericin B, tetracycline, and nitrofurantoin. Penicillin, a beta-lactamase antibacterial medication, is utilized to manage a wide range of infections, including urinary tract infections (UTIs). It is effective against common bacteria causing UTIs and is generally well-tolerated. Indications for penicillin in urinary tract infection treatment include both complicated and uncomplicated UTIs. Distribution channels encompass hospital pharmacies, gynecology and urology clinics, drug stores, retail pharmacies, and online drug stores.
The urinary tract infection treatment market research report is one of a series of new reports that provides urinary tract infection treatment market statistics, including the urinary tract infection treatment industry global market size, regional shares, competitors with a urinary tract infection treatment market share, detailed urinary tract infection treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the urinary tract infection treatment industry. This urinary tract infection treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The urinary tract infection treatment market consists of sales of trimethoprim, sulfamethoxazole, cephalexin, and ceftriaxone. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The urinary tract infection treatment market size is expected to see steady growth in the next few years. It will grow to $12.45 billion in 2029 at a compound annual growth rate (CAGR) of 3.7%. The growth in the forecast period can be attributed to development of non-antibiotic treatments, rise in resistant bacterial strains, personalized treatment approaches, elemedicine and remote consultations, public health awareness programs. Major trends in the forecast period include microbiome-based therapies, phage therapy, point-of-care testing, nutritional interventions, preventive strategies focus, community-based interventions.
The increasing prevalence of urinary tract infections is poised to drive the expansion of the market for urinary tract infection treatment in the future. Urinary tract infections encompass bacterial infections affecting various parts of the urinary system, including the kidneys, bladder, ureters, and urethra. Effective treatment of urinary tract infections is crucial in addressing the infection and fostering healing. As of January 2023, the National Institute of Health reported that urinary tract infections ranked as the seventh most common reason for emergency department visits in the USA, constituting over one million annual visits. Of these cases, 22% (220,000) were considered complicated UTIs, with around 100,000 resulting in hospital admissions. Consequently, the increasing prevalence of urinary tract infections is a significant driver of growth in the urinary tract infection treatment market.
The aging population is anticipated to be a catalyst for the expansion of the urinary tract infection treatment market. The term 'aging population' refers to a demographic shift characterized by a rising proportion of elderly individuals within a society or population. The elderly demographic requires urinary tract infection (UTI) treatment due to an elevated susceptibility to UTIs associated with age-related factors such as weakened immune function and alterations in urinary tract structure. As of October 2022, the World Health Organization highlighted that the global population of individuals aged 60 years and older is rapidly growing, projected to double by 2050, reaching 2.1 billion. Hence, the increasing aging population is propelling the growth of the urinary tract infection treatment market.
The adoption of advanced diagnostic technologies is an emerging trend gaining traction in the urinary tract infection treatment market. Companies in the market are focusing on innovative product development to maintain their competitive positions. In April 2023, AccessDx Laboratory, a US-based diagnostic laboratory, introduced the UTI PROx Panel. UTI PROx is designed to provide healthcare providers with enhanced insights to improve clinical care and decision-making when dealing with suspected, complex, and recurrent urinary tract infections.
Major companies operating in the urinary tract infection treatment market are concentrating on the development of innovative products such as Harncare bearberry tablets. These tablets serve as an herbal remedy for symptoms associated with lower urinary tract infections. Harncare Bearberry Tablets, formulated with the single crude drug bearberry, is the first tablet of its kind in Japan and is available as a second-class over-the-counter drug in pharmacies and drugstores across the country. In March 2022, Taiho Pharmaceutical Co. Ltd., a Japan-based pharmaceutical company, launched Harncare Bearberry tablets, addressing urinating discomfort and the sensation of residual urine.
In September 2022, GSK plc, a UK-based biopharmaceutical company, announced a licensing agreement with Spero Therapeutics, Inc. for tebipenem pivoxil hydrobromide (tebipenem HBr). This partnership aims to enable GSK to develop and commercialize tebipenem HBr, an innovative oral antibiotic designed to treat complicated urinary tract infections, thereby addressing a critical unmet medical need for effective alternatives to intravenous therapies. Spero Therapeutics, Inc. is a US-based biopharmaceutical company focused on treating urinary tract infections.
Major companies operating in the urinary tract infection treatment market include Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck & Co. Inc, AbbVie Inc., Allergan Plc, Bayer AG, Novartis International AG., Sanofi S.A., Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., AstraZeneca plc, GlaxoSmithKline PLC, Eli Lilly and Company, Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries Ltd, Dr. Reddy's Laboratories Ltd., Bio-Rad Laboratories Inc., Cipla Ltd, Hikma Pharmaceuticals PLC, Lupin Limited, Almirall SA, Torrent Pharmaceuticals Limited, Glenmark Pharmaceuticals Limited, Mylan N.V.
North America was the largest region in the urinary tract infection treatment market in 2024. The regions covered in the urinary tract infection treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the urinary tract infection treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Urinary tract infection treatment involves medical procedures and methods aimed at eliminating bacterial infections affecting the urinary system, which can impact areas such as the bladder, urethra, ureters, kidneys, and other components of the urinary system.
The main types of drug classes in urinary tract infection treatment include penicillin and combinations, quinolones, cephalosporin, aminoglycoside antibiotics, Sulfonamides, azoles and amphotericin B, tetracycline, and nitrofurantoin. Penicillin, a beta-lactamase antibacterial medication, is utilized to manage a wide range of infections, including urinary tract infections (UTIs). It is effective against common bacteria causing UTIs and is generally well-tolerated. Indications for penicillin in urinary tract infection treatment include both complicated and uncomplicated UTIs. Distribution channels encompass hospital pharmacies, gynecology and urology clinics, drug stores, retail pharmacies, and online drug stores.
The urinary tract infection treatment market research report is one of a series of new reports that provides urinary tract infection treatment market statistics, including the urinary tract infection treatment industry global market size, regional shares, competitors with a urinary tract infection treatment market share, detailed urinary tract infection treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the urinary tract infection treatment industry. This urinary tract infection treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The urinary tract infection treatment market consists of sales of trimethoprim, sulfamethoxazole, cephalexin, and ceftriaxone. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Urinary Tract Infection Treatment Market Characteristics3. Urinary Tract Infection Treatment Market Trends and Strategies4. Urinary Tract Infection Treatment Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid and Recovery on the Market32. Global Urinary Tract Infection Treatment Market Competitive Benchmarking and Dashboard33. Key Mergers and Acquisitions in the Urinary Tract Infection Treatment Market34. Recent Developments in the Urinary Tract Infection Treatment Market
5. Global Urinary Tract Infection Treatment Growth Analysis and Strategic Analysis Framework
6. Urinary Tract Infection Treatment Market Segmentation
7. Urinary Tract Infection Treatment Market Regional and Country Analysis
8. Asia-Pacific Urinary Tract Infection Treatment Market
9. China Urinary Tract Infection Treatment Market
10. India Urinary Tract Infection Treatment Market
11. Japan Urinary Tract Infection Treatment Market
12. Australia Urinary Tract Infection Treatment Market
13. Indonesia Urinary Tract Infection Treatment Market
14. South Korea Urinary Tract Infection Treatment Market
15. Western Europe Urinary Tract Infection Treatment Market
16. UK Urinary Tract Infection Treatment Market
17. Germany Urinary Tract Infection Treatment Market
18. France Urinary Tract Infection Treatment Market
19. Italy Urinary Tract Infection Treatment Market
20. Spain Urinary Tract Infection Treatment Market
21. Eastern Europe Urinary Tract Infection Treatment Market
22. Russia Urinary Tract Infection Treatment Market
23. North America Urinary Tract Infection Treatment Market
24. USA Urinary Tract Infection Treatment Market
25. Canada Urinary Tract Infection Treatment Market
26. South America Urinary Tract Infection Treatment Market
27. Brazil Urinary Tract Infection Treatment Market
28. Middle East Urinary Tract Infection Treatment Market
29. Africa Urinary Tract Infection Treatment Market
30. Urinary Tract Infection Treatment Market Competitive Landscape and Company Profiles
31. Urinary Tract Infection Treatment Market Other Major and Innovative Companies
35. Urinary Tract Infection Treatment Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Urinary Tract Infection Treatment Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on urinary tract infection treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for urinary tract infection treatment? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The urinary tract infection treatment market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Drug Class: Penicillin and Combinations; Quinolones; Cephalosporin; Aminoglycoside Antibiotics; Sulphonamides; Azoles and Amphotericin B; Tetracycline; Nitrofurantoin2) By Indication: Complicated UTI; Uncomplicated UTI
3) By Distribution Channel: Hospital Pharmacies; Gynecology and Urology Clinics; Drug Stores; Retail Pharmacies; Online Drug Store
Subsegments:
1) By Penicillin and Combinations: Amoxicillin; Ampicillin; Amoxicillin or Clavulanate2) By Quinolones: Ciprofloxacin; Levofloxacin; Norfloxacin
3) By Cephalosporin: Cephalexin; Ceftriaxone; Cefotaxime
4) By Aminoglycoside Antibiotics: Gentamicin; Tobramycin; Amikacin
5) By Sulphonamides: Sulfamethoxazole or Trimethoprim; Sulfadiazine
6) By Azoles and Amphotericin B: Fluconazole; Itraconazole; Amphotericin B
7) By Tetracycline: Doxycycline; Minocycline
8) By Nitrofurantoin: Nitrofurantoin Monohydrate; Nitrofurantoin Macrocrystals
Key Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd; Merck & Co. Inc; AbbVie Inc.; Allergan Plc
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Pfizer Inc.
- F. Hoffmann-La Roche Ltd
- Merck & Co. Inc
- AbbVie Inc.
- Allergan Plc
- Bayer AG
- Novartis International AG.
- Sanofi S.A.
- Bristol-Myers Squibb Company
- Thermo Fisher Scientific Inc.
- AstraZeneca plc
- GlaxoSmithKline PLC
- Eli Lilly and Company
- Boehringer Ingelheim GmbH
- Teva Pharmaceutical Industries Ltd
- Sun Pharmaceutical Industries Ltd
- Dr. Reddy's Laboratories Ltd.
- Bio-Rad Laboratories Inc.
- Cipla Ltd
- Hikma Pharmaceuticals PLC
- Lupin Limited
- Almirall SA
- Torrent Pharmaceuticals Limited
- Glenmark Pharmaceuticals Limited
- Mylan N.V.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | February 2025 |
| Forecast Period | 2025 - 2029 |
| Estimated Market Value ( USD | $ 10.78 Billion |
| Forecasted Market Value ( USD | $ 12.45 Billion |
| Compound Annual Growth Rate | 3.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 25 |
